Fontolizumab
Based on 1 Customer Validation
Fontolizumab (HuZAF) is a human monoclonal antibody targeting interferon γ (IFN-γ). Fontolizumab binds specifically and with high affinity to secreted IFN-γ, neutralizes its activity, blocks receptor binding, and inhibits downstream signal transduction and the expression of IFNγ-responsive genes. Fontolizumab reduces serum C-reactive protein levels, inhibits the expression of IL-1α, IL-1β and IL-12Rβ2, and decreases the number of IFNγ-producing T cells in activated peripheral blood mononuclear cells. Fontolizumab can be used in research related to Crohn's disease.
For research use only. We do not sell to patients.
- Purity: 97.18%
- CAS No.: 326859-36-3
- Molecular Weight:144.8 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG1 kappa
Human
|
IFN-γ |
Fontolizumab (100 μg/mL; 24 h) suppresses IFNγ-associated gene and protein expression in activated human PBMCs, with a 7.0-fold reduction in IFNG mRNA and ~30% reduction in IFNγ-producing CD3+ T cells, while not significantly affecting T-cell activation or viability[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 326859-36-3
-
Appearance Liquid
-
Molecular Weight 144.8 kDa
-
Color Colorless to light yellow
-
SMILES
[Fontolizumab]
-
Synonyms
HuZAF; Anti-Human IFNG Recombinant Antibody
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Hommes DW, et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut. 2006 Aug;55(8):1131-7. [Content Brief]
[2]. Reinisch W, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut. 2006 Aug;55(8):1138-44. [Content Brief]
[3]. Reinisch W, et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflammatory bowel diseases. 2010 Feb;16(2):233-42. [Content Brief]
[5]. Haider AS, et al. Insights into gene modulation by therapeutic TNF and IFNgamma antibodies: TNF regulates IFNgamma production by T cells and TNF-regulated genes linked to psoriasis transcriptome. The Journal of investigative dermatology. 2008 Mar;128(3):655-66. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Fontolizumab Related Classifications
HY-P99292 Related Classifications
Powered by Bioz